Lump sum or DCA, the latest on Ozempic & a baby Berkshire?
Haven't heard much about Ozempic lately? Let us change that and bring you up to speed on some wild developments in the world of weight loss drugs. In this episode we cover: How Novo Nordisk's latest drug has been twice as effective as their existing drugs in early trialsThe growing list of competitors to OzempicWhy…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Equity Mates Investing Podcast
See all episodes →
68%Replace your salary with dividend income
63%Not all income is created equal with Helen Mason | Schroders
62%Data centre resistance grows, CSL is (sort of) back & a stock picker joins Pimp my Portfolio
Similar episodes from other shows
More like Equity Mates Investing Podcast →
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.